CLINICAL_TRIALS
trial_result
· 2026-02-10
Clinical Trial Update: Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant [Phase 2]
Summary
Phase 2 study of Daratumumab (Darzalex) in relapsed multiple myeloma after stem cell transplant was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2026-02-10